Q32 Bio Inc.

NASDAQ:QTTB

Biotechnology

Healthcare
$8.53 -1.70%

-$0.22 today

Market cap
$255.25M
Beta
-0.23
P/E (TTM)
5.4
EPS (TTM)
$2.36
52W Low $1.35High $14.85

Volume 0.26M

Average 0.74M

QTTB Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Q32 Bio Inc.NASDAQ: QTTB

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity turns positive

Q1 FY2026 total equity was $46.31M, compared with -$4.01M a year earlier.

Context

  • Total equity amounted to 72.7% of total assets at the end of Q1 FY2026, up 67.7 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +1253.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$46.31M+10.2% QoQ
Last fiscal yearDec 2025
$42.01M+640.3% YoY
Year agoMar 2025
-$4.01M+1253.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1253.8%——
1 year+640.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
42.01M USD
Year-over-year change
+640.3%
4-year CAGR
-29.5%

Total Equity vs competitors

How QTTB compares with its peers on the latest reported figures

  • QTTB's Mar 2026 total equity of $46.31M is the 4th highest of the 5 companies compared; the peer median is $84.07M.
  • Its year-over-year change of +1253.8% is the 2nd highest of 5, against a peer median of +99.0%.
  • Total equity amounts to 72.7% of total assets for QTTB, versus a peer median of 75.7%.
QTTB Competitors Peer median
Total Equity for QTTB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SABSSAB Biotherapeutics, Inc.Jun 2026$214.79M +1687.5%+69.6%90.2%
BOLDBoundless Bio, Inc.Mar 2026$86.38M -36.8%—61.3%
ANTXAN2 Therapeutics, Inc.Mar 2026$81.76M +11.5%-17.8%93.4%
QTTBQ32 Bio Inc.Mar 2026$46.31M +1253.8%—72.7%
VRCAVerrica Pharmaceuticals Inc.Mar 2026$16.06M +186.4%-14.8%41.4%
Peer median (excluding QTTB) $84.07M+99.0%-14.8%75.7%

Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents108.38M43.89M25.62M77.97M48.3M
Short-term Investments47.49M0000
Net Receivables01.06M755K555K0
Inventory01.75M000
Other Current Assets36.04M146K83K396K6.75M
Total Current Assets191.91M46.85M28.72M81.88M55.05M
Property, Plant & Equipment (Net)17.86M9.17M8.08M7.09M6.08M
Goodwill00000
Intangible Assets00000
Long-term Investments1.95M25.81M5.65M2.6M647K
Tax Assets00000
Other Non-current Assets0(20.06M)10.26M763K0
Total Non-current Assets19.81M14.92M18.34M10.46M6.73M
Total Assets211.72M61.77M47.06M92.33M61.78M
Account Payables2.37M1.44M3.47M2.99M879K
Short-term Debt246K32.4M878K3.1M6.93M
Tax Payables0570K316K00
Deferred Revenue3.21M14.53M000
Other Current Liabilities11.41M2.79M3M5.68M3.54M
Total Current Liabilities17.23M57.87M14.11M16.47M11.35M
Long-term Debt05.07M43.18M9.56M3.47M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.16M11.32M000
Other Non-current Liabilities0111.45M166.45M55M0
Total Non-current Liabilities24.84M134.62M215.87M70.19M8.42M
Total Liabilities42.07M192.49M229.98M86.66M19.76M
Common Stock6K6K1K2K2K
Retained Earnings(424.13M)(429.14M)(187.08M)(234.81M)(204.99M)
Accumulated OCI(7K)(404K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity169.65M(130.71M)(182.92M)5.68M42.01M
Total Debt23.93M44.73M50.84M18.9M15.34M
Net Debt(84.45M)838K25.22M(59.06M)(32.95M)

Q32 Bio Inc.

NASDAQ:QTTB

Intrinsic Alpha fair value

Locked

Current Price

$8.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.